Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer.... It is also being investigated for preventing SARSCOV-2 viral entry.
- Mechanism
- Curator reviewed
Rexin G is a non-pathogenic entity that mimics SARS-COV2 by binding to receptors to gain entry into human cells. It is being investigated for preventing SARSCOV-2 viral entry, and also acts as an inhibitor of the cyclin G1 pathway.
- Also known as
- DeltaRex-G · DeltaRex-G Retroviral Vector Encoding a Cyclin G1 Inhibitor · Mx-dnG1 retroviral vector · retroviral expression vector bearing anti-cyclin G1 gene construct
- Code names
- Mx-dnG1
Resolves to
What you can answer from here — as of September 30, 2025
Which companies are running trials of Rexin G, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account